Best practice in the management of behavioural and psychological symptoms of dementia

Therapeutic Advances in Neurological Disorders

Volumn 10, Issue 8, 2017, Pages 297-309

  Tible, Olivier Pierre ^a   Riese, Florian ^b,c   Savaskan, Egemen ^b   Von Gunten, Armin ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY HOSPITAL OF PSYCHIATRY   (Switzerland)

^c UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

attachment; BPSD; environmental factors; etiopathogenetic; individualized treatment; personality

Indexed keywords

ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; MOOD STABILIZER; NEUROLEPTIC AGENT; NOOTROPIC AGENT;

AGGRESSION; AGITATION; ALZHEIMER DISEASE; ANXIETY DISORDER; APATHY; CLINICAL FEATURE; COGNITIVE BEHAVIORAL THERAPY; DELUSION; DEMENTIA; DEPRESSION; DISEASE SEVERITY; ENVIRONMENTAL FACTOR; EXERCISE; FRONTOTEMPORAL DEMENTIA; HALLUCINATION; HUMAN; LIFE EVENT; MUSIC THERAPY; NEUROMODULATION; NEUROTRANSMISSION; NURSING CARE; PAIN; PATIENT CARE; PERSONALITY; PHOTOTHERAPY; PRIORITY JOURNAL; PSYCHOEDUCATION; PSYCHOPHARMACOTHERAPY; PSYCHOTHERAPY; REALITY ORIENTATION THERAPY; REMINISCENCE THERAPY; REVIEW; RISK FACTOR; SENSORY STIMULATION; SLEEP DISORDER; VALIDATION THERAPY;

EID: 85025091463     PISSN: 17562856     EISSN: 17562864     Source Type: Journal    
DOI: 10.1177/1756285617712979     Document Type: Review

References (114)

1. International Psychogeriatric Association. The IPA complete guides to behavioral and psychological symptoms of dementia. Milwaukee, WI: International Psychogeriatric Association, 2010, www.ipa-online.org/publications/guides-to-bpsd (. accessed 30 September 2010).
2. Steinberg M, Shao H, Zandi P, et al. Point and 5-year period prevalence of neuropsychiatric symptoms in dementia: the Cache County Study. Int J Geriatr Psychiatry 2008; 23: 170-177.
3. Devshi R, Shaw S, Elliott-King J, et al. Prevalence of behavioural and psychological symptoms of dementia in individuals with learning disabilities. Diagnostic 2015; 5: 564-576.
4. Kales HC, Gitlin LN, Lyketsos CG., Management of neuropsychiatric symptoms of dementia in clinical settings: recommendations from a multidisciplinary expert panel. Similar to DICE (diagnose, investigate, create, evaluate). J Am Geriatr Soc 2014; 62: 762-769.
5. Perez Romero A, Gonzalez Garrido S,. The importance of behavioral and psychological symptoms in Alzheimer's disease. Neurologia. DOI: 10.1016/j.nrl.2016.02.024.
6. Savaskan E, Bopp-Kistler I, Buerge M, et al. Therapy guidelines for the behavioural and psychological symptoms of dementia. Praxis 2014; 103: 135-148.
7. Canevelli M, Adali N, Cantet C, et al. Impact of behavioral subsyndromes on cognitive decline in Alzheimer's disease: data from the ICTUS study. J Neurol 2013; 260: 1859-1865.
8. Feast A, Moniz-Cook E, Stoner C, et al. A systematic review of the relationship between behavioral and psychological symptoms (BPSD) and caregiver well-being. Int Psychogeriatr 2016; 28: 1761-1774.
9. Nourhashémi F, Andrieu S, Sastres N, et al. Descriptive analysis of emergency hospital admissions of patients with Alzheimer disease. Alzheimer Dis Assoc Disord 2001; 15: 21-25.
10. Toot S, Swinson T, Devine M, et al. Causes of nursing home placement for older people with dementia: a systematic review and meta-analysis. Int Psychogeriatr 2016; 3: 1-14.
11. Yafee K, Fox P, Newcomer R, et al. Patient and caregiver characteristics and nursing home placement in patients with dementia. JAMA 2002; 287: 2090-2097.
12. Beeri MS, Werner P, Davidson M, et al. The cost of BPSD in community dwelling Alzheimer's disease patients. Int J Geriatr Psychiatry 2002; 17: 403-408.
13. Kraft E, Marti M, Werner S, et al. Cost of dementia in Switzerland. Swiss Med Wkly 2010; 140: w13093.
14. Kales HC, Gitlin LN, Lyketsos CG., Assessment and management of behavioral and psychological symptoms of dementia. BMJ 2015; 350: h369.
15. Gitlin LN, Marx KA, Stanley IH, et al. Assessing neuropsychiatric symptoms in people with dementia: a systematic review of measures. Int Psychogeriatr 2014; 26: 1805-1848.
16. Cummings JL, Mega M, Gray K, et al. The neuropsychiatric inventory: comprehensive assessment of psychopathology in dementia. Neurology 2014; 44: 2308-2314.
17. Reisberg B, Borenstein J, Salob SP, et al. Behavioral symptoms in Alzheimer's disease: phenomenology and treatment. J Clin Psychiatry 1987; 48 (Suppl.): 9-15.
18. Jeon YH, Sansoni J, Low LF, et al. Recommended measures for the assessment of behavioral disturbances associated with dementia. Am J Geriatr Psychiatry 2011; 19: 403-415.
19. Aalten A, Verhey FR, Boziki M, et al. Consistency of neuropsychiatric syndromes across dementias: results from the European Alzheimer Disease Consortium. Part II. Dement Geriatr Cogn Disord 2008; 25: 1-8.
20. Lyketsos CG, Lopez O, Jones B, et al. Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the Cardiovascular Health Study. JAMA 2002; 288: 1475-1483.
21. Mega MS, Cummings JL, Fiorello T, et al. The spectrum of behavioral changes in Alzheimer's disease. Neurology 1996; 46: 130-135.
22. Van der Linde RM, Dening T, Stephan BCM, et al. Longitudinal course of behavioural and psychological symptoms of dementia: systematic review. Br J Psychiatry 2016; 209: 366-377.
23. Elflein HM, Rudy M, Lorenz K, et al. Charles Bonnet's syndrome: not only a condition of the elderly. Graefes Arch Clin Exp Ophthalmol 2016; 254: 1637-1642.
24. Cummings J, Mintzer J, Brodaty H, et al. Agitation in cognitive disorders: International Psychogeriatric Association provisional consensus clinical and research definition. Int Psychogeriatr 2015; 27: 7-17.
25. Gnanasekaran G., 'Sundowning' as a biological phenomenon: current understandings and future directions: an update. Aging Clin Exp Res 2016; 28: 383-392.
26. Cohen-Mansfield J, Golander H, Ben-Israel J, et al. The meaning of delusions in dementia: a preliminary study. Psychiatry Res 2011; 189: 97-104.
27. Cipriani G, Danti S, Vedovello M, et al. Understanding delusion in dementia: a review. Geriatr Gerontol Int 2014; 14: 32-39.
28. Cohen-Mansfield J, Cohen R, Golander H, et al. The impact of psychotic symptoms on the persons with dementia experiencing them. Am J Geriatr Psychiatry 2016; 24: 213-220.
29. Cipriani G, Vedovello M, Ulivi M, et al. Delusional misidentification syndromes and dementia: a border zone between neurology and psychiatry. Am J Alzheimers Dis Other Demen 2013; 28: 671-678.
30. Lanctôt KL, Agüera-Ortiz L, Brodaty H, et al. Apathy associated with neurocognitive disorders: recent progress and future directions. Alzheimers Dement 2017; 13: 84-100.
31. Robert PH, Clairet S, Benoit M, et al. The apathy inventory: assessment of apathy and awareness in Alzheimer's disease, Parkinson's disease and mild cognitive impairment. Int J Geriatr Psychiatry 2002; 17: 1099-1105.
32. Van der Linde RM, Matthews FE, Dening T, et al. Patterns and persistence of behavioural and psychological symptoms in those with cognitive impairment: the importance of apathy. Int J Geriatr Psychiatry. 32 (3): 306-315. DOI: 10.1002/gps.4464.
33. Bubu OM, Brannick M, Mortimer J, et al. Sleep, cognitive impairment and Alzheimer's disease: a systematic review and meta-analysis. Sleep 2017; 40: zsw032.
34. Ooms S, Ju YE., Treatment of sleep disorders in dementia. Curr Treat Options Neurol 2016; 18: 40.
35. McCleery J, Cohen DA, Sharpley AL., Pharmacotherapies for sleep disturbances in dementia. Cochrane Database Syst Rev 2016; 16: CD009178.
36. Heller J, Brcina N, Dogan I, et al. Brain imaging findings in idiopathic REM sleep behavior disorder (RBD): a systematic review on potential biomarkers for neurodegeneration. Sleep Med Rev. DOI: 10.1016/j.smrv.2016.06.006.
37. Cagnin A, Fragiacomo F, Camporese G, et al. Sleep-wake profile in dementia with Lewy bodies, Alzheimer's disease and normal aging. J Alzheimer Dis 2016; 55: 1529-1536.
38. McCarter SJ St, Louis EK, Boeve BF., Sleep disturbances in frontotemporal dementia. Curr Neurol Neurosci Rep 2016; 16: 85.
39. Mitchell AJ., Neuropsychiatry and behavioural neurology explained. Edinburgh: Saunders, 2004, p. 536.
40. Bizdan M, Bidzan L, Pachalska M., Neuropsychiatric symptoms in patients with Alzheimer's disease with a vascular component. Ann Agric Environ Med 2014; 21: 412-415.
41. Kazui H, Yoshiyama K, Kanemoto H, et al. Differences of behavioral and psychological symptoms of dementia in disease severity in four major dementias. PLoS One 2016; 11: e0161092.
42. Bang J, Spina S, Miller BL., Frontotemporal dementia. Lancet 2015; 386: 1672-1682.
43. Clerc MT, Von Gunten A., Frontotemporal lobar degeneration. In: Tanner P, (eds) Dementia: prevalence, risk factors and management strategies. Hauppauge (Headquarters), New York: Nova Science Publishers, 2014, pp. 87-114.
44. Engelborghs S, Vloeberghs E, Le Bastard N, et al. The dopaminergic neurotransmitter system is associated with aggression and agitation in frontotemporal dementia. Neurochem Int 2008; 52: 1052-1060.
45. Von Gunten A, Bouras C, Kövari E, et al. Neural substrates of cognitive and behavioral deficits in atypical Alzheimer's disease. Brain Res Rev 2006; 51: 176-211.
46. Huey ED, Lee S, Devanand DP., Brain regions involved in arousal and reward processing are associated with apathy in Alzheimer's disease and frontotemporal dementia. J Alzheimer Dis 2016; 55: 551-558.
47. Torso M, Serra L, Giulietti G, et al. Strategic lesions in the anterior thalamic radiation and apathy in early Alzheimer's disease. PLoS One 2015; 10: e0124998.
48. Makovac E, Serra L, Spano B, et al. Different patterns of correlation between grey and white matter integrity account for behavioral and psychological symptoms in Alzheimer's disease. J Alzheimers Dis 2016; 50: 591-604.
49. Tokuchi R, Hishikawa N, Sato K, et al. Age-dependent cognitive and affective differences in Alzheimer's and Parkinson's diseases in relation to MRI findings. J Neurol Sci 2016; 365: 3-8.
50. Minger SL, Esiri MM, McDonald B, et al. Cholinergic deficits contribute to behavioral disturbance in patients with dementia. Neurology 2000; 55: 1460-1467.
51. Lagarde J, Sarazin M, Chauviré V, et al. Cholinergic changes in aging and Alzheimer disease: an 18F-F-A 85380 exploratory PET study. Alzheimer Dis Assoc Disord. 31 (1): 8-12. DOI: 10.1097/WAD000000000163.
52. Herrmann N, Lanctôt KL, Khan LR., The role of norepinephrine in the behavioral and psychological symptoms of dementia. J Neuropsychiatry Clin Neurosci 2004; 16: 261-276.
53. David R, Koulibaly M, Benoit M, et al. Striatal dopamine transporter levels correlate with apathy in neurodegenerative diseases: a SPECT study with partial volume effect correction. Clin Neurol Neurosurg 2008; 110: 19-24.
54. Mitchell RA, Herrmann N, Lanctôt KL., The role of dopamine in symptoms and treatment of apathy in Alzheimer's disease. CNS Neurosci Ther 2011; 17: 411-427.
55. Gould E., Serotonin and hippocampal neurogenesis. Neuropsychopharmacology 1999; 21 (Suppl. 2): 46S-51S.
56. Poletti S, Locatelli C, Falini A, et al. Adverse childhood experiences associate to reduced glutamate levels in the hippocampus of patients affected by mood disorders. Prog Neuropsychopharmacol Biol Psychiatry 2016; 71: 117-122.
57. Ribeiro FM, Vieira LB, Pires RG, et al. Metabolic glutamate receptors and neurodegenerative diseases. Pharmacol Res 2016; 115: 179-191.
58. Maidment ID, Haw C, Stubbs J, et al. Medication errors in older people with mental health problems: a review. Int J Geriatr Psychiatry 2008; 23: 564-573.
59. Yesavage JA, Noda A, Hernandez B., Circadian clock gene polymorphisms and sleep-wake disturbance in Alzheimer disease. Am J Geriatr Psychiatry 2011; 19: 635-643.
60. Mulin E, Zeitzer JM, Yesavage J, et al. Relationship between apathy and sleep disturbance in mild and moderate Alzheimer's disease: an actigraphic study. J Alzheimers Dis 2011; 25: 85-91.
61. Zheng Z, Wang J, Yi L, et al. Correlation between behavioural and psychological symptoms of Alzheimer type dementia and plasma homocysteine concentration. Biomed Res Int 2014: 383494.
62. Flirski M, Sobow T, Kloszewska I., Behavioural genetics of Alzheimer's disease: a comprehensive review. Arch Med Sci 2011; 7: 195-210.
63. Kolaczkowski M, Marcinkowska M, Bucki A, et al. Novel 5-HT6 receptor antagonists/D2 receptor partial agonists targeting behavioral and psychological symptoms of dementia. Eur J Med Chem 2015; 92: 221-235.
64. Stefano P, Concetta C, Luigi D, et al. Role of neurodevelopment involved genes in psychiatric comorbidities and modulation of inflammatory processes in Alzheimer's disease. J Neurol Sci 2016; 370: 162-166.
65. Tible O., Présentation des équipes mobiles de Psychogériatrie, Brussels, Belgium, 7-9 September 2016. Société de Psychogériatrie de Langue Française, 32ème Congrès de Psychogériatrie de langue française, pp. 25-26, www.splf-2016.org (accessed 9 September 2016).
66. Malara A, De Biase GA, Bettarini F, et al. Pain assessment in elderly with behavioral and psychological symptoms of dementia. J Alzheimers Dis 2016; 50: 1217-1225.
67. Pocnet C, Rossier J, Antonietti JP, et al. Personality changes in patients with beginning Alzheimer disease. Can J Psychiatry 2011; 56: 408-417.
68. Pocnet C, Rossier J, Antonietti JP, et al. Personality traits and behavioral and psychological symptoms in patients at an early stage of Alzheimer's disease. Int J Geriatr Psychiatry 2013; 28: 276-283.
69. Prior J, Abraham R, Nicholas H, et al. Are premorbid abnormal personality traits associated with behavioural and psychological symptoms in dementia? Int J Geriatr Psychiatry 2016; 31: 1050-1055.
70. Boyle LL, Lyness JM, Duberstein PR, et al. Trait neuroticism, depression, and cognitive function in older primary care patients. Am J Geriatr Psychiatry 2010; 18: 305-312.
71. Johansson L, Guo X, Duberstein PR, et al. Midlife personality and risk of Alzheimer disease and distress: a 38-year follow-up. Neurology 2014; 83: 1538-1544.
72. Von Gunten A, Pocnet C, Rossier J,. The impact of personality characteristics on the clinical expression in neurodegenerative disorders: a review. Brain Res Bull 2009; 80: 179-191.
73. Hirshfeld-Becker DR, Micco J, Henin A, et al. Behavioral inhibition. Depress Anxiety 2008; 25: 357-367.
74. Schwartz CE, Hirshfeld-Becker DR, Henin A, et al. Behavioral inhibition in childhood predicts smaller hippocampal volume in adolescent offspring of parents with panic disorder. Transl Psychiatry 2015; 21: e605.
75. Van Rooij SJ, Kennis M, Vink M, et al. Childhood trauma and COMT genotype interact to increase hippocampal activation in resilient individuals. Front Psychiatry 2016; 14: 156.
76. Bradley JM, Cafferty TP., Attachment among older adults: current issues and directions for future research. Attachment Hum Dev 2001; 3: 200-221.
77. Browne CJ, Shlosberg E., Attachment theory, ageing and dementia: a review of the literature. Aging Ment Health 2006; 10: 134-142.
78. Magai C, Cohen CI, Culver C, et al. Relation between premorbid personality and patterns of emotion expression in mid- to late-stage dementia. Int J Geriatr Psychiatry 1997; 12: 1092-1099.
79. Fujii M, Butler JP, Sasaki H., Emotional function dementia patients. Psychogeriatrics 2014; 14: 202-209.
80. Feast A, Orrell M, Russell I, et al. The contribution of caregiver psychosocial factors to distress associated with behavioral and psychological symptoms in dementia. Int J Geriatr Psychiatry 2017; 32: 76-85.
81. Corbett A, Husebo B, Malcangio M, et al. Assessment and treatment of pain in people with dementia. Nat Rev Neurol 2012; 8: 264-274.
82. Ouslander J, Bartesl S, Beck C, et al. Consensus statement on improving the quality of mental health care in US nursing homes: management of depression and behavioral symptoms associated with dementia. J Am Geriatr Soc 2003; 51: 1287-1298.
83. S3-Leitlinie Demenzen. In: Deutsche Gesellschaft für Neurologie, HRSG; Leitlinien für Diagnostik und Therapie in der Neurologie., www.dgn.org/leitlinien (2016, accessed 27 January 2016).
84. Livingston G, Kelly L, Lewis-Holmes E, et al. Non-pharmacological interventions for agitation in dementia: systematic review of randomized controlled trials. Br J Psychiatry 2014; 205: 436-442.
85. Abraha I, Rimland JM, Trotta FM, et al. Systematic review of systematic reviews of non-pharmacological interventions to treat behavioural disturbances in older patients with dementia. The SENATOR-On Top series. BMJ Open 2017; 7: 3: e012759.
86. Livingston G, Johnston K, Katona C, et al. Systematic review of psychological approaches to the management of neuropsychiatric symptoms of dementia. Am J Psychiatry 2005; 162: 1996-2021.
87. Hepburn K, Lewis M, Tornatore J, et al. The Savvy Caregiver program: the demonstrated effectiveness of a transportable dementia caregiver programme. J Gerontol Nurs 2007; 33: 30-36.
88. Copper C, Mukadam N, Katona C, et al. Systematic review of the effectiveness of non-pharmacological interventions to improve quality of life of people with dementia. Int Psychogeriatr 2012; 24: 856-870.
89. Schoenmakers B, Buntinx F, DeLepeleire J., Supporting the dementia family caregiver: the effect of home care intervention on general well-being. Aging Ment Health 2010; 14: 44-56.
90. Kolanowski A., An overview of the need-driven dementia-compromised behavior model. J Gerontol Nurs 1999; 25: 7-9.
91. Kovach CR, Noonan PE, Schlidt AM, et al. The serial trial intervention: an innovative approach to meeting needs of individuals with dementia. J Gerontol Nurs 2006; 32: 18-25.
92. McMinn B, Draper B., Vocally disruptive behaviour in dementia: development of an evidence based practice guideline. Aging Ment Health 2005; 9: 16-24.
93. Hajjar RR, Kamel HK., Sexuality in the nursing home, part 1: attitudes and barriers to sexual expression. J Am Med Dir Assoc 2004; 5: 42-47.
94. Heyn P, Abreu BC, Ottenbacher KJ., The effects of exercise training on elderly patients with cognitive impairment and dementia: a meta-analysis. Arch Phys Med Rehabil 2004; 85: 1694-1704.
95. Scholey KA, Woods BT., A series of brief cognitive therapy interventions with people experiencing both dementia and depression: a description of techniques and common themes. Clin Psychol Psychiatry 2003; 10: 175-185.
96. Brodaty H, Arasaratnam C., Meta-analysis of nonpharmacological interventions for neuropsychiatric symptoms of dementia. Am J Psychiatry 2012; 169: 946-953.
97. Sörensen S, Pinquart M, Duberstein P., How effective are interventions with caregivers? An updated meta-analysis. Gerontologist 2002; 42: 356-372.
98. Trinh NH, Hoblyn J, Mohanty S, et al. Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer's disease: a meta-analysis. JAMA 2003; 289: 210-216.
99. Howard RJ, Juszczak E, Ballard CG, et al. Donepezil for the treatment of agitation in Alzheimer's disease. N Engl J Med 2007; 357: 1382-1392.
100. Gauthier S, Loft H, Cummings J., Improvement in behavioural symptoms in patients with moderate to severe Alzheimer's disease by memantine: a pooled data analysis. Int J Geriatr Psychiatry 2008; 23: 537-545.
101. Wilcock GK, Ballard CG, Cooper JA, et al. Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer's disease: a pooled analysis of 3 studies. J Clin Psychiatry 2008; 69: 341-348.
102. Von Gunten A., Schwabe Symposium on BPSD: prevalence, clinical importance and treatment options. Second Congress of the European Academy of Neurology, 28-31 May 2016, Copenhagen, Denmark, www.ean.org (accessed 31 May 2016).
103. Fox C, Crugel M, Maidment I, et al. Efficacy of memantine for agitation in Alzheimer's dementia: a randomized double-blind placebo controlled trial. PLoS One 2012; 7: e35185.
104. Ballard C, Thomas A, Gerry S, et al. A double-blind randomized placebo-controlled withdrawal trial comparing memantine and antipsychotics for the long-term treatment of function and neuropsychiatric symptoms in people with Alzheimer's disease (MAIN-AD). J Am Med Dir Assoc 2015; 16: 316-322.
105. Von Gunten A, Schlaefke S, Überla K,. Efficacy of Gingko Biloba extract EGb 761® in dementia with behavioural and psychological symptoms: a systematic review. World J Biol Psychiatry 2016; 17: 622-633.
106. Lyketsos CG, Del Campo L, Steinberg M, et al. Treating depression in Alzheimer disease: efficacy and safety of sertraline therapy, and the benefits of depression reduction: the DIADS. Arch Gen Psychiatry 2003; 60: 737-746.
107. Porsteinsson AP, Drye LT, Pollock BG, et al. Effect of citalopram on agitation in Alzheimer disease: the citAD randomized clinical trial. JAMA 2014; 311: 682-691.
108. Ballard C, Waite J., The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease. Cochrane Database Syst Rev 2006; 25: CD003476.
109. Maher AR, Maglione M, Bagley S, et al. Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis. JAMA 2011; 306: 1359-1369.
110. Reus VI, Fochtmann LJ, Eyler AE, et al. The American Psychiatric Association practice guideline on the use of antipsychotics to treat agitation or psychosis in patients with dementia. Am J Psychiatry 2016; 173: 543-546.
111. Tariot PN, Schneider L, Katz IR, et al. Quetiapine treatment of psychosis associated with dementia: a double-blind, randomized, placebo-controlled clinical trial. Am J Geriatr Psychiatry 2006; 14: 767-776.
112. Kurlan R, Cummings J, Raman R, et al. Quetiapine for agitation or psychosis in patients with dementia and parkinsonism. Neurology 2007; 68: 1356-1363.
113. Ballard CG, Gauthier S, Cummings JL, et al. Management of agitation and aggression associated with Alzheimer disease. Nat Rev Neurol 2009; 5: 245-255.
114. Zhou QP, Jung L, Richards KC., The management of sleep and circadian disturbance in patients with dementia. Curr Neurol Neurosci Rep 2012; 12: 193-204.